Supernus Pharmaceuticals Inc has a consensus price target of $40.5, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Piper Sandler, and Piper Sandler on February 28, 2024, November 9, 2023, and October 25, 2023. With an average price target of $42 between Piper Sandler, Piper Sandler, and Piper Sandler, there's an implied 23.13% upside for Supernus Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/28/2024 | SUPN | Buy Now | Supernus Pharmaceuticals | $34.11 | 20.2% | Piper Sandler | David Amsellem | $45 → $41 | Maintains | Overweight | Get Alert |
11/09/2023 | SUPN | Buy Now | Supernus Pharmaceuticals | $34.11 | 26.06% | Piper Sandler | David Amsellem | $42 → $43 | Maintains | Overweight | Get Alert |
10/25/2023 | SUPN | Buy Now | Supernus Pharmaceuticals | $34.11 | 23.13% | Piper Sandler | David Amsellem | $43 → $42 | Maintains | Overweight | Get Alert |
05/10/2023 | SUPN | Buy Now | Supernus Pharmaceuticals | $34.11 | 34.86% | Piper Sandler | David Amsellem | $45 → $46 | Maintains | Overweight | Get Alert |
01/23/2023 | SUPN | Buy Now | Supernus Pharmaceuticals | $34.11 | 37.79% | Piper Sandler | David Amsellem | $40 → $47 | Maintains | Overweight | Get Alert |
08/31/2022 | SUPN | Buy Now | Supernus Pharmaceuticals | $34.11 | 11.4% | Piper Sandler | David Amsellem | $33 → $38 | Maintains | Overweight | Get Alert |
04/13/2021 | SUPN | Buy Now | Supernus Pharmaceuticals | $34.11 | 17.27% | Jefferies | David Steinberg | — | Upgrade | Hold → Buy | Get Alert |
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on February 28, 2024. The analyst firm set a price target for $41.00 expecting SUPN to rise to within 12 months (a possible 20.20% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.
The last upgrade for Supernus Pharmaceuticals Inc happened on April 13, 2021 when Jefferies raised their price target to $40. Jefferies previously had a hold for Supernus Pharmaceuticals Inc.
There is no last downgrade for Supernus Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on February 28, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $45.00 to $41.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $34.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.